A granulocytic signature identifies COVID-19 and its severity

A granulocytic signature identifies COVID-19 and its severity. Vitte J, Diallo AB, Boumaza A, Lopez A, Michel M, Allardet-Servent J, Mezouar S, Sereme Y, Busnel JM, Miloud T, Malergue F, Morange PE, Halfon P, Olive D, Leone M, Mege JL. J Infect Dis. 2020 Sep 17:jiaa591. doi: 10.1093/infdis/jiaa591. Online ahead of print. PMID: 32941618

Summary

Unsupervised mapping of leukocyte surface markers identified a granulocytic COVID-19 signature comprising eosinophil and basophil CRTH2 downregulation, increased counts of CD15+CD16+ neutrophils, and decreased granulocytic CD11b expression, while PDL1 checkpoint expression in basophils and eosinophils was associated with severity.

All papers

Our partners

International Eosinophil Society (IES) European Centre for Allergy Research Foundation (ECARF) DFG Priority Programme SPP 1394 “Mast cells” European Academy of Allergy and Clinical Immunology (EAACI) European Competence Network on Mastocytosis (ECNM) European Histamine Research Society (EHRS) European Cooperation in Science and Technology (COST) Global Allergy and Asthma Excellence Network (GA²LEN)

Your help is appreciated!

If you want to support our activities by donation or if you want to become a sponsor of EMBRN, please contact us.